Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.

A user shared an 8.5-month update on their hair transplant of 1064 grafts done by Dr. Kaan Pekiner in Ankara, Turkey, costing $3500. They are also using finasteride 2.25 mg weekly and have reduced shampoo use.

A new topical treatment, TH07, combining finasteride, latanoprost, and minoxidil, is entering phase III trials with promising early results. Some users express skepticism, noting the treatment uses existing products.

The user experienced significant hair loss after using RU58841, a hair loss treatment, and had to undergo a hair transplant to rectify the damage. They're asking others who've used RU58841 about their experiences, particularly if they also experienced shedding, if their hair grew back, when they started using RU, and other related questions.

The conversation discusses the appearance and testing of RU58841 powder for hair loss treatment. Users also mention side effects of RU58841 and suggest alternatives like dutasteride and minoxidil.

The conversation is about hair loss treatments, specifically the anticipation for the release of a new treatment, GT20029, by 2028. Users are discussing their experiences with current treatments like finasteride and dutasteride, and the potential of future treatments, including FAK inhibitors and verteporfin trials.

RU58841 was the only treatment that slowed hair loss and reduced irritation for a DUPA sufferer after trying finasteride, minoxidil, and dutasteride with no success. The user continues using 6mg oral minoxidil, 0.5mg dutasteride, and an 8% RU58841 solution.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also inquires about the timeline for the GT20029 phase 3 trial by Kintor.

Hair loss treatment progress with Dut, Min, Keto, needling, and RU/Min/Fin/Dut topical. User noticed improvement, believes RU and needling most effective.

The relative strength of Pyrilutamide compared to RU58841 in terms of androgen receptor binding affinity. It has been noted that Pyrilutamide is 4x stronger than RU58841, with a higher binding affinity than DHT itself.

The user started using a hair loss treatment called pyrilutamide and experienced mild chest discomfort and tightness, similar to previous side effects from RU58841. They plan to reduce the dosage due to these side effects and will provide an update on the results in 1-2 months.

Actifolic's RU58841 and Pyri products are perceived as ineffective, with users reporting no side effects or improvements, suggesting possible quality issues. Users recommend alternative sources and emphasize the importance of timing when using RU58841 with Minoxidil.

The conversation is about hair loss and the use of specific treatments like minoxidil, finasteride, and RU58841.

Setipiprant trial for hair loss failed, showing no difference between placebo and treatment. Discussion also noted placebo users reporting side effects.

A 59-year-old man with significant hair loss has seen some improvement, including reversal of Retrograde Alopecia and darkening of hair, after switching to RU58841 and a new minoxidil base solution with additional ingredients. He also changed from a derma roller to a derma stamp for application.

RU58841 is being discussed for its effects on hair loss. The user has started using RU58841 with finasteride and is curious about its potential for hair maintenance or regrowth.

The user is experiencing significant hair shedding after starting RU58841, despite using dutasteride and oral minoxidil for over a year without stabilization. Others suggest continuing the treatment as shedding can be a normal phase, but caution that RU58841 is unpredictable.

A six month update of the users' experience with Pyrilutamide, a hair loss treatment that combines Minoxidil, Finasteride and RU58841.

RU58841 may cause heart-related side effects like palpitations and chest pain, though evidence is mostly anecdotal. Users report mixed experiences, with some stopping due to side effects and others using it without issues, but concerns about its safety and sourcing remain.

The conversation discusses disappointment with the hair loss treatment KX-826 but notes that the company Kintor is still focused on developing and commercializing it, as stated in their 2023 annual report. The user questions the effectiveness of KX-826 in comparison to minoxidil's role in improving hair thickness and appearance.

RU-58642 is a powerful anti-androgen that was not developed further, possibly due to safety concerns or financial reasons. RU58841 is a topical alternative, but it is less effective than finasteride and dutasteride, and its long-term effects are not well-studied.

GT20029 is a potential treatment for androgenetic alopecia, addressing the root cause by targeting androgen receptors, unlike Minoxidil or Finasteride. It is seen as a preventative measure rather than a regrowth agent, with hopes for market release soon.

User experienced hair thickening and slight regrowth using RU58841, Fin, DUT, and Minoxidil. They plan to get a hair transplant in Turkey for further improvement.

The conversation discusses the sale of a premixed KY19382 solution for research purposes, highlighting previous unsuccessful group buys and the formulation process. Prices and purchasing options for KY19382 solutions and powder are provided.

A 32-year-old male shares his 5-year progress using finasteride, minoxidil, RU58841, and ketoconazole for hair loss. Despite consistent use, he feels his hair isn't as thick as before and is concerned about continued shedding and hairline miniaturization.

A user is considering whether to continue using RU58841 or switch to hair system patches for a receding hairline, while already using finasteride, oral minoxidil, and microneedling. Another user suggests buying RU58841 in powder form to save money and notes the original poster's hair has significantly improved.

A peptide from Japanese water chestnut fruit may help with hair loss by suppressing DHT's effect on hair follicle cell death, potentially serving as a finasteride alternative. The treatment's effectiveness and safety in humans remain uncertain.

The user has been using topical minoxidil (5%) for two years and kx826/pyrilutamide for one year, after experiencing side effects from finasteride. They report positive results from the combination of minoxidil and kx826 in combating hair loss.

A 23-year-old male is experiencing diffuse hair loss and miniaturization, possibly due to high IGE levels after using tofacitinib. He seeks advice and has not yet consulted a dermatologist.

A user created a tracker for hair loss treatments in clinical development, including compounds like Dermaliq, RU58841, and Pyrilutamide. The tracker updates with new information and allows filtering by conditions like androgenetic alopecia (AGA) and alopecia areata (AA).